TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01837134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedical (TM) group
Description: telemedical devices (weighing machine and step counter)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedical (TM) group
Description: telemedical devices (weighing machine and step counter)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telemedical coaching (TMC) group
Description: care calls once per week for 12 weeks
Study: NCT04177446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: a production consist of various oligopeptides and the whey protein
Description: patients will be given extra protein intake except the basic energy intake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: basic energy intake
Description: supplement as basic energy intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: basic energy intake
Description: supplement as basic energy intake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: used as placebo in the control group
Study: NCT02083627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fidaxomicin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fidaxomicin
Description: Oral
Study: NCT02289872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh Laryngoscope
Description: Direct-Laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh Laryngoscope
Description: Direct-Laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh Laryngoscope
Description: Direct-Laryngoscopy
Study: NCT02427776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope
Description: 1 administration comprising 5 - 50 millions of cells
Study: NCT02173587

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mussel oil capsules
Description: Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil capsules
Description: Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
Study: NCT00724633

Intervention type: OTHER
Group type: OTHER
Intervention: Lowering the dialysate sodium
Description: Please see above

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lowering the dialysate sodium
Description: Please see above

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lowering the dialysate sodium
Description: Please see above
Study: NCT04635514

Intervention type: PROCEDURE
Intervention: Lateral colporrhaphy
Study: NCT03857542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine HCl Ophthalmic Solution
Description: Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle, one drop in each eye, once daily, for up to 30 days.
Study: NCT04412707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Peripheral versus central administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Peripheral versus central administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral tablets
Study: NCT01548196

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Percutaneous nephrolithotomy
Description: Percutaneous nephrolithotomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Percutaneous nephrolithotomy
Description: Percutaneous nephrolithotomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Percutaneous nephrolithotomy
Description: Percutaneous nephrolithotomy
Study: NCT05532280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg film coated tablet
Description: an immediate-release tablet containing 90 mg of Etoricoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arcoxia 90 mg film coated tablet
Description: an immediate-release tablet containing 90 mg of Etoricoxib
Study: NCT00924339

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein diet
Description: Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: rapeseed oil
Description: Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
Study: NCT02356692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: Control lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Control lens
Study: NCT02413541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polymyxin-B Hemoperfusion
Description: Endotoxin removal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Study: NCT02159521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EkoSonic® Endovascular System

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Recombinant tissue plasminogen activator
Study: NCT03265197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-tympanic injection of drugs
Description: Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data management of intratympanic drugs
Description: intervention by statistical analysis of Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
Study: NCT00490074

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DNA-C
Description: 1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-C
Description: 1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NYVAC-C
Description: NYVAC-C 1 ml IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-C
Description: NYVAC-C 1 ml IM
Study: NCT02202369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Analgesia Treatment
Description: Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Pain Management Protocol
Description: Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
Study: NCT01900808

Intervention type: DEVICE
Intervention: Trained operator with M probe.
Description: Trained operator with M probe: non-drug intervention, baseline comparator.
Study: NCT02181062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Intervention
Description: 4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age.
Study: NCT00776646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide 50 mg tablet
Study: NCT01900808

Intervention type: DEVICE
Intervention: Experienced operator with M probe.
Description: Experienced operator with M probe: non-drug intervention, longitudinal comparator.

Intervention type: DEVICE
Intervention: Experienced operator with XL probe.
Description: Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
Study: NCT02477189

Intervention type: PROCEDURE
Intervention: Silicone Block
Study: NCT04381650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.
Study: NCT05820984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIRIT checklist plus usual practice
Description: Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (12) Sample size (14) Recruitment (15) Allocation implementation (16 c) Blinding (17 a) Data collection methods (18 a) Data collection methods - retention (18 b) Statistical methods (20 a) Population analysed (20 c) Access to data (29)

Intervention type: OTHER
Group type: OTHER
Intervention: Usual practice
Description: Peer review as it is usual practice at the journal
Study: NCT01930721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: episiotomy
Description: incision angle of episiotomy will be 60 degrees.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: episiotomy
Description: incision angle of episiotomy will be 40 degree before cutting.
Study: NCT03811301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainConnexion
Description: A 4.4mm by 4.2mm electrode array is placed onto the surface of the motor cortex which is then connected to a miniaturized neural recording microsystem that transmits signals wirelessly to control an external assistive device. Neural signals are recorded at least once every week for 12 months or longer.
Study: NCT03203434

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary volatile organic compound analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary volatile organic compound analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary volatile organic compound analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary volatile organic compound analysis
Study: NCT00776646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide 50 mg tablet
Study: NCT01985425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Colchicine
Study: NCT04341948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study: NCT04649177

Intervention type: DEVICE
Group type: OTHER
Intervention: Ocular surface optical coherence tomography
Description: EYEdeal Scanning technology enables rapid measurement of the corneal and scleral topography which provides data for an automated sequence to fit PROSE devices
Study: NCT02335593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Sulphate
Description: Zinc Sulphate Hard Gel capsules 110mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn Starch filled Hard Gel Capsules
Description: Corn Starch filled Hard Gel Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa 2000-4000 IU solution for injection
Description: Epoetin alfa 2000-4000 IU solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 2000-4000 IU solution for injection
Description: Epoetin alfa 2000-4000 IU solution for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Hydroxide Saccharate Complex Solution for injection
Description: Iron Hydroxide Saccharate Complex Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Hydroxide Saccharate Complex Solution for injection
Description: Iron Hydroxide Saccharate Complex Solution for injection
Study: NCT00474617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocurium
Description: intravenous (IV) single bolus dose of 0.6 mg.kg-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocurium
Description: intravenous (IV) single bolus dose of 0.6 mg.kg-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocurium
Description: intravenous (IV) single bolus dose of 0.6 mg.kg-1
Study: NCT06480149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMALC
Description: Classical shoulder massage was applied to both shoulders of the patient for 10-15 minutes each.

Intervention type: OTHER
Group type: OTHER
Intervention: no application
Description: In the control group, there was no massage application and only pain and sleep quality were evaluated.
Study: NCT01502163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoflect [TM] passive insulation
Description: passive insulation in the preoperative phase, befor induction of anesthesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)
Description: Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
Study: NCT01115374

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual lymphatic drainage
Description: Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low frequency sound waves
Description: Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
Study: NCT03723746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.
Study: NCT02264132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole IR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole IR tablet
Study: NCT01750008

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Global Fibroid Ablation
Study: NCT04616222

Intervention type: DRUG
Intervention: CELSIOR® group
Description: Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.

Intervention type: DRUG
Intervention: Saint-Thomas group
Description: Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
Study: NCT04164420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral neuromuscular training and orofacial sensory-vibration
Description: Oral neuromuscular training is performed by using an oral device. The device is placed pre-dentally behind closed lips, and the participant is sitting in an up-right position. The participant is the instructed to hold the device against a gradually-increasing horizontal pulling force for 5-10 s, whilst trying to resist the force by tightening the lips and pressing the head backward against a head rest.
Study: NCT01029639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)
Description: Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
Study: NCT02493556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT before muscle damage

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LLLT before muscle damage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT after muscle damage

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LLLT after muscle damage
Study: NCT03326856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: topical liniment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: topical liniment
Study: NCT04164420

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial sensory-vibration stimulation
Description: All participants in the control group is given orofacial sensory-vibration stimulation by using an electrical toothbrush. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
Study: NCT01750008

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Myomectomy
Study: NCT02970279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation Group (BAG) Psychotherapy
Description: Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
Study: NCT01428180

Intervention type: DRUG
Intervention: Indomethacin
Description: 3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)

Intervention type: PROCEDURE
Intervention: Surgical Ligation
Description: In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.

Intervention type: DRUG
Intervention: Ibuprofen
Description: 3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
Study: NCT02206555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine/tenofovir disoproxil fumarate
Study: NCT03837561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cunox
Description: Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.